ArticlePediatric rheumatology online journal2011
Partial response to anakinra in life-threatening Henoch-Schönlein purpura: case report.
Article in Pediatric rheumatology online journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Biologics for immunoglobulin A vasculitis: targeting vasculitis or comorbid disease?Internal and emergency medicine · 2022Article
- Kawasaki disease: pathophysiology and insights from mouse models.Nature reviews. Rheumatology · 2020Review
- Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis-A Critical Review of Its Pathogenesis and Treatment.Frontiers in pediatrics · 2020Review
- Henoch-Schönlein Purpura in children: not only kidney but also lung.Pediatric rheumatology online journal · 2019Review
- Intestinal Permeability and IgA Provoke Immune Vasculitis Linked to Cardiovascular Inflammation.Immunity · 2019Article
- The Future of IL-1 Targeting in Kidney Disease.Drugs · 2018Review
- Anakinra Therapy for Non-cancer Inflammatory Diseases.Frontiers in pharmacology · 2018Review
- Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.Rheumatology international · 2017Review
- Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease.Journal of the American Society of Nephrology : JASN · 2016Review
- An expanding role for interleukin-1 blockade from gout to cancer.Molecular medicine (Cambridge, Mass.) · 2014Review
- Treating inflammation by blocking interleukin-1 in humans.Seminars in immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Henoch-Schönlein purpura is one of the most common forms of systemic vasculitis of childhood. We report the response to anakinra, the interleukin-1 receptor antagonist, in a 9 year old girl without prior medical problems who developed life-threatening Henoch-Schönlein vasculitis that produced renal failure, pulmonary hemorrhage and vasculitis of the brain. Her response supports the theory that interleukin-1 may be an important mediator in this disease. Further study of interleukin-1 antagonists in severe Henoch-Schönlein purpura may be warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.